Abstract:Imre Barta, 1, &ast Csilla Paska, 1, &ast Balazs Antus 1, 2 1 Department of Pathophysiology, National Koranyi Institute of Pulmonology, Budapest, Hungary; 2 Department of Pulmonology, National Koranyi Institute of Pulmonology, Budapest, Hungary &astThese authors contributed equally to this work Correspondence: Balazs Antus, Department of Pathophysiology, National Koranyi Institute of Pulmonology, Koranyi Frigyes ut 1, Tel +36 1 391 3309, Fax +36 1 200 7060, Email Purpose: Cytokines are extracellular signaling proteins that have been widely implicated in the pathogenesis of chronic obstructive pulmonary disease (COPD). Here, we investigated cytokine expression both at the mRNA and protein level in the sputum of healthy individuals, stable COPD patients, and those experiencing a severe acute exacerbation (AECOPD) requiring hospitalization. Patients and Methods: Sputum was collected in 19 healthy controls, 25 clinically stable COPD patients, and 31 patients with AECOPD. In AECOPD patients sample collection was performed both at the time of hospital admission and at discharge following treatment. Sputum supernatant was analyzed by an antibody microarray detecting 120 cytokines simultaneously, while the mRNA expression of 14 selected cytokines in sputum cells was investigated by real-time PCR (qPCR). Results: Proteomic analysis identified interleukin (IL)-6 and growth-regulated oncogene (GRO)α as the only sputum cytokines that were differentially expressed between stable COPD patients and healthy controls. At the onset of AECOPD, several cytokines exhibited altered sputum expression compared to stable COPD. Recovery from AECOPD induced significant changes in the sputum cytokine protein profile; however, the length of hospitalization was insufficient for most cytokines to return to stable levels. With regard to gene expression analysis by qPCR, we found that bone morphogenetic protein (BMP)-4 was up-regulated, while IL-1α, monokine-induced by interferon-γ (MIG), and BMP-6 were down-regulated at the mRNA level in patients with AECOPD compared to stable disease. Conclusion: The sputum cytokine signature of AECOPD differs from that of stable COPD. Protein level changes are asynchronous with changes in gene expression at the mRNA level in AECOPD. The observation that the levels of most cytokines do not stabilize with acute treatment of AECOPD suggests a prolonged effect of exacerbation on the status of COPD patients. Keywords: airway, biomarker, gene, inflammation, microarray, PCR Chronic obstructive pulmonary disease (COPD) is an inflammatory lung disease characterized by increased numbers of macrophages, neutrophils and T cells, and enhanced release of various inflammatory mediators. 1 Nonetheless, the airway inflammation in COPD is heterogeneous: the most common inflammatory phenotype is the neutrophil-associated COPD with inflammasome, Th1 and Th17 activation, while in a minority of patients increased eosinophilic airway inflammation with increased Th2-transcriptome signature can be observed. 2 It is well established that cytokines and chemokines play a key role in the control of these inflammatory processes. 3,4 Cytokines secreted from T cells primarily regulate the pattern of inflammation, whereas pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-α, interleukin (IL)-1β or IL-6 amplify inflammation, in part through the activation of the transcription factor (NF)-κB, thereby resulting in increased expression of several inflammatory genes. Chemokines, in turn, recruit inflammatory cells from the circulation to the lungs, while growth factors maintain this inflammation and are mainly involved in the development of the characteristic structural changes of the airways, in particular small airway disease and empyhsema. 5 In recent years tremendous efforts have been put forward to profile these inflammatory processes in order to better understand the molecular mechanisms underlying the disease and provide a rationale for biological agents targeting specific inflammatory pathways. 6,7 However, it has proved difficult to identify distinct inflammatory endotypes among COPD patients, and associations between inflammatory mechanisms and clinical manifestations of the disease remained uncertain in most cases. 8 Protein microarray is an established technology to assess the proteome of biological samples. 9 The major advantage of using this method is that it allows the detection of a large number of factors simultaneously in a single experiment. Sputum is a valuable source of cytokines, chemokines, and inflammatory proteins, 10 and there is evidence -Abstract Truncated-

Sputum Inflammatory Cell-Based Classification of Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease.

Determination of Biomarkers in Exhaled Breath Condensation of Acute Exacerbation of Chronic Obstructive Pulmonary Disease and Its Clinical Implications

Correlation of Inflammatory Cells in Induced Sputum and Peripheral Blood of Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Characteristics of the Sputum Microbiome in COPD Exacerbations and Correlations Between Clinical Indices

Inflammatory Biomarkers in induced Sputum Predict Chronic Obstructive Pulmonary Disease (COPD) Severity

The Sputum Microbiome Associated with Different Sub-Types of AECOPD in a Chinese Cohort

Alterations of Plasma Inflammatory Biomarkers in the Healthy and Chronic Obstructive Pulmonary Disease Patients with or Without Acute Exacerbation.

Evaluation of Blood Markers at Admission for Predicting Community Acquired Pneumonia in Chronic Obstructive Pulmonary Disease

Dynamic Gene Expressions of Peripheral Blood Mononuclear Cells in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease: a Preliminary Study.

Serum Glycerophospholipid Profile in Acute Exacerbation of Chronic Obstructive Pulmonary Disease.

Analysis of clinical features of acute exacerbated chronic obstructive pulmonary disease patients

Sputum Cytokine Profiling in COPD: Comparison Between Stable Disease and Exacerbation

Inflammatory Endotype-associated Airway Microbiome in Chronic Obstructive Pulmonary Disease Clinical Stability and Exacerbations: A Multicohort Longitudinal Analysis.

Bacterial Infection, Airway and Systemic Inflammation and Clinical Outcomes Before and after Treatment of AECOPD, a Longitudinal and Cross-Sectional Study.

Correlation of Serum Clara Cell Secretory Protein 16, Plasma Fibrinogen and Serum Amyloid A with the Severity of Acute Exacerbated COPD and Their Combination in Prognosis Assessment

Serum Inflammatory Factor and Cytokines in AECOPD

Study of New Inflammatory Cellular Phenotypes in AECOPD and Inflammatory Factors in Subgroups

Identification of Sputum Biomarkers Predictive of Pulmonary Exacerbations in COPD.

Analysis of sputum microbial flora in chronic obstructive pulmonary disease patients with different phenotypes during acute exacerbations

Clinical differences between eosinophilic and non-eosinophilic acute exacerbation of chronic obstructive pulmonary disease (AECOPD), a multicenter cross-sectional study

Association between peripheral blood WBCs C3aR mRNA level and plasma C3a, C3aR, IL-1β concentrations and acute exacerbation of chronic obstructive pulmonary disease